Aniflumab shows potential for refractory discoid lupus

Published Date: 28 Mar 2023

This study evaluated data from 8 women with clinically refractory SLE who were treated with anifrolumab for at least 8 weeks.

Read Full News

Latest News

Warning: Patient's Itchy Swollen Skin Patches Were Not Infectious Cellulitis

Five years of inappropriate antibiotic treatment finally ended after proper diagnosis

10-Year Data Back Early Start to Biologics in Arthritic Diseases

— Sustained drug-free remission common in spondyloarthritis patients treated with golimumab

Shingles Recurrence or Something Worse?

Bedside skin punch biopsy proved crucial

Skin Problems, Kidney Complaints, and Venous Issues Spike During Heat Waves

Study suggests attention to heat-related problems besides heat stroke

First Oral Option for Dermatomyositis Gets FDA Green Light

Brepocitinib significantly improved overall symptom status in a phase III trial

A Call to End Routine Laboratory Monitoring for Patients on Isotretinoin

Streamlined testing still overkill given lack of evidence for hepatotoxicity, pancreatitis

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

HTTP error: 503

— Sustained drug-free remission common in spondyloarthritis patients treated with golimumab
HTTP error: 503

Study suggests attention to heat-related problems besides heat stroke
HTTP error: 503

Streamlined testing still overkill given lack of evidence for hepatotoxicity, pancreatitis

News All Time

US Regulators Urge More Research on Testosterone Therapy for Women as Experts Debate Benefits, Risks

US health regulators on Thursday called for more data on testosterone therapies for women, with FDA officials urging manufacturers to conduct studies that could support...

FDA Grants Priority Review for Diabetic Foot Ulcer Therapy

The FDA has granted priority review for a novel wound-healing therapy for Wagner Grade 1 diabetic foot ulcers.

Pennsylvania Measles Cases Top 700 After Four Outbreak-related Deaths Reported

The Pennsylvania Department of Health on Wednesday reported 731 measles cases, up 38 from Monday's ⁠update, as the outbreak continued to spread in the state at the center of...

Fear of Relapse Burdens Patients With Vitiligo

Nearly half of patients with vitiligo who achieve repigmentation fear losing treatment gains, with relapse-related anxiety affecting psychological well-being even when skin improvement is maintained.
HTTP error: 503HTTP error: 503

A Decade After Mercury Ban, Toxic Skin Bleachers Still Offered on Top Retailers' Websites

(Removes errant quote marks in paragraph 14)

Pennsylvania Measles-associated Deaths Climb to Four as Outbreak Grows

The Pennsylvania Department of Health on Tuesday reported two more measles-associated deaths, both in unvaccinated individuals, bringing the state's total fatalities linked...

FDA Grants Priority Review to Zasocitinib for Psoriasis

Zasocitinib is also being evaluated in phase 3 studies for psoriatic arthritis and in phase 2 studies for Crohn’s disease, ulcerative colitis, vitiligo, and hidradenitis suppurativa.

Serious Infections Lower With Anifrolumab in CLE Patients

Anifrolumab, approved for systemic lupus, is currently being evaluated in a phase 3 study in patients with cutaneous lupus erythematosus.
HTTP error: 503

Prior Keratinocyte Carcinoma Tied to Mucosal Melanoma

A history of keratinocyte carcinoma was associated with more than four times the odds of mucosal melanoma, study reports.

Trust in Measles Vaccines Falls in US, Reuters Ipsos Poll Finds

Americans' trust in vaccines for deadly childhood diseases including measles has fallen in recent years, a new Reuters/Ipsos poll found, a troubling sign for the country as...
HTTP error: 503

Pembrolizumab Benefits Persist in Cervical Cancer

After 5 years of follow-up, pembrolizumab plus chemotherapy continues to demonstrate sustained survival advantages in patients with persistent, recurrent, or metastatic cervical cancer.

Criteria for Prescribing Testosterone: Who Qualifies?

A Brazilian multidisciplinary consensus sets thresholds for the diagnosis and treatment while emphasizing symptom assessment, repeated testing, and attention to the underlying causes.

Recommended News For You

Recommended Articles For You

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot